// App-Quantinova.ai

ABS055 : BAY 94‐9027 PROVIDED EFFECTIVE LONG‐TERM PROPHYLAXIS IN PEDIATRIC PATIENTS AGED ≥ 12 YEARS AT THE END OF THE PROTECT VIII KIDS EXTENSION STUDY, INDICATING CONSISTENT SAFETY OF TREATMENT INTO ADOLESCENCE

Researchers

Presenter

  • S. Ahuja

Principal Investigators

  • K. Fischer

  • T. Biss

  • M. Maas Enriquez

  • M. E. Mancuso

  • M. Steele

  • M. Wang

  • G. Kenet

Medical Centers

  • Rainbow Hemostasis & Thrombosis Center, University Hospitals Rainbow Babies and Children’s Hospital, Case Western Reserve University School of Medicine, Cleveland, United States

  • Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

  • Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

  • Bayer Pharma AG, Berlin, Germany

  • Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy; Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan, Italy

  • Cumming School of Medicine, Alberta Children’s Hospital, University of Calgary, Calgary, Canada

  • Bayer, Whippany, United States

  • Israel National Hemophilia Center and Thrombosis Unit, Chaim Sheba Medical Centre, Tel‐Hashomer, Israel

Locations

  • United States

  • Netherlands

  • United Kingdom

  • Germany

  • Italy

  • Canada

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01775618

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved